m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and...

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer death, often diagnosed late.
• Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown promise but faces challenges like tumor heterogeneity and immune evasion.
• Understanding the tumor immune microenvironment (TIME) is crucial for improving HCC treatment outcomes.

Purpose of the Study:

• To review the role of N6-methyladenosine (m6A) RNA modification in shaping the HCC TIME.
• To explore how m6A influences immune cells, cytokine dynamics, and PD-L1 expression.
• To discuss the therapeutic potential of targeting m6A for enhancing immunotherapy efficacy in HCC.

Main Methods:

• Literature review focusing on m6A modification in HCC.
• Analysis of m6A's impact on immune cell function and cytokine profiles within the TIME.
• Examination of m6A regulators as biomarkers and therapeutic targets.

Main Results:

• m6A modification plays a key role in regulating RNA stability and translation of immune-related factors in HCC.
• m6A influences PD-L1 expression, contributing to immune escape and ICI resistance.
• m6A-related regulators are identified as potential biomarkers for immunotherapy response.

Conclusions:

• m6A modification is a critical determinant of the HCC immune microenvironment.
• Targeting m6A pathways presents a promising strategy to overcome immunotherapy resistance in HCC.
• Further research into m6A mechanisms can lead to novel therapeutic approaches for advanced HCC.